Cover Image
市場調查報告書

視力保健:醫療設備的開發平台評估

Vision Care - Medical Devices Pipeline Assessment, 2016

出版商 GlobalData 商品編碼 350916
出版日期 內容資訊 英文 298 Pages
訂單完成後即時交付
價格
Back to Top
視力保健:醫療設備的開發平台評估 Vision Care - Medical Devices Pipeline Assessment, 2016
出版日期: 2016年12月01日 內容資訊: 英文 298 Pages
簡介

本報告提供視力保健的開發中產品調查分析,以各開發階段比較分析為焦點,提供您正在開發開發中產品的主要企業,進行中的臨床試驗相關資訊等系統性資訊。

第1章 目錄

第2章 簡介

  • 視力保健概要

第3章 開發中的產品

  • 視力保健 - 開發中產品:各開發階段
  • 視力保健 - 開發中產品:各市場區隔
  • 視力保健 - 開發中產品:各地區
  • 視力保健 - 開發中產品:法規別
  • 視力保健 - 開發中產品:核准預定日別
  • 視力保健 - 進行中的臨床試驗

第4章 視力保健 - 正在開發的開發中產品:各企業

  • 視力保健企業 - 開發中產品:各開發階段
  • 視力保健 - 開發中產品:各開發階段

第5章 視力保健企業與產品概要

  • Adventus Technology Inc
  • Alcon, Inc.
  • Apeliotus Ophthalmics
  • Auburn University
  • Axcelon Biopolymers Corp.
  • Bar-Ilan University
  • Bausch & Lomb Incorporated
  • Belfanti - Fureder - Meidl technisches Buro f Elektro u Haustechnik GmbH
  • Bionic Vision Australia
  • Body Organ Biomedical Corp.
  • Children's Hospital Boston
  • Consejo Superior de Investigaciones Cientificas
  • CooperVision, Inc.
  • Cornell University
  • EP Global Communications, Inc.
  • eSight Corporation
  • Euclid Systems Corporation
  • Eyegenix
  • EyeNetra, Inc.
  • Eyenovations等

第6章 視力保健 - 最近的趨勢

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0270EPD

GlobalData's Medical Devices sector report, "Vision Care - Medical Devices Pipeline Assessment, 2016" provides an overview of Vision Care currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Vision Care pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Vision Care under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Vision Care and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Vision Care under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Vision Care Overview

3. Products under Development

  • 3.1. Vision Care - Pipeline Products by Stage of Development
  • 3.2. Vision Care - Pipeline Products by Segment
  • 3.3. Vision Care - Pipeline Products by Territory
  • 3.4. Vision Care - Pipeline Products by Regulatory Path
  • 3.5. Vision Care - Pipeline Products by Estimated Approval Date
  • 3.6. Vision Care - Ongoing Clinical Trials

4. Vision Care - Pipeline Products under Development by Companies

  • 4.1. Vision Care Companies - Pipeline Products by Stage of Development
  • 4.2. Vision Care - Pipeline Products by Stage of Development

5. Vision Care Companies and Product Overview

  • 5.1. Adventus Technology Inc Company Overview
    • 5.1.1. Adventus Technology Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Aeon Astron Corporation Company Overview
    • 5.2.1. Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Alcon, Inc. Company Overview
    • 5.3.1. Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Apeliotus Ophthalmics Company Overview
    • 5.4.1. Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Auburn University Company Overview
    • 5.5.1. Auburn University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Axcelon Biopolymers Corp. Company Overview
    • 5.6.1. Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Bar-Ilan University Company Overview
    • 5.7.1. Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. Bausch & Lomb Inc Company Overview
    • 5.8.1. Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Bionic Eye Technologies, Inc. Company Overview
    • 5.9.1. Bionic Eye Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. Bionic Vision Australia Company Overview
    • 5.10.1. Bionic Vision Australia Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Children's Hospital Boston Company Overview
    • 5.11.1. Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Consejo Superior de Investigaciones Cientificas Company Overview
    • 5.12.1. Consejo Superior de Investigaciones Cientificas Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. CooperVision Inc Company Overview
    • 5.13.1. CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. Cornea Biosciences Company Overview
    • 5.14.1. Cornea Biosciences Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. Cornell University Company Overview
    • 5.15.1. Cornell University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. EP Global Communications, Inc. Company Overview
    • 5.16.1. EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. eSight Corporation Company Overview
    • 5.17.1. eSight Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Euclid Systems Corporation Company Overview
    • 5.18.1. Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. Eyenovations Company Overview
    • 5.19.1. Eyenovations Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. EyeYon Medical Company Overview
    • 5.20.1. EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21. iBionics Inc Company Overview
    • 5.21.1. iBionics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22. Imperial College London Company Overview
    • 5.22.1. Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23. iSTAR Medical SA Company Overview
    • 5.23.1. iSTAR Medical SA Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24. John Hopkins University Company Overview
    • 5.24.1. John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25. Johnson & Johnson Vision Care Inc Company Overview
    • 5.25.1. Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26. Massachusetts Eye and Ear Infirmary Company Overview
    • 5.26.1. Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview
  • 5.27. McGill University Company Overview
    • 5.27.1. McGill University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.28. Mercy Research and Development Company Overview
    • 5.28.1. Mercy Research and Development Pipeline Products & Ongoing Clinical Trials Overview
  • 5.29. Meta Biomed Co Ltd Company Overview
    • 5.29.1. Meta Biomed Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.30. Microbiosensor Ltd Company Overview
    • 5.30.1. Microbiosensor Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.31. Monash University Company Overview
    • 5.31.1. Monash University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.32. Nano Retina, Inc. Company Overview
    • 5.32.1. Nano Retina, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.33. Novartis AG Company Overview
    • 5.33.1. Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.34. Ocular Dynamics, LLC Company Overview
    • 5.34.1. Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.35. Ocutec Ltd Company Overview
    • 5.35.1. Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.36. PixelOptics Inc Company Overview
    • 5.36.1. PixelOptics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.37. Pixium Vision Company Overview
    • 5.37.1. Pixium Vision Pipeline Products & Ongoing Clinical Trials Overview
  • 5.38. Presbia Plc Company Overview
    • 5.38.1. Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.39. Queensland University of Technology Company Overview
    • 5.39.1. Queensland University of Technology Pipeline Products & Ongoing Clinical Trials Overview
  • 5.40. Refocus Group Inc Company Overview
    • 5.40.1. Refocus Group Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.41. RetMap Inc Company Overview
    • 5.41.1. RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.42. ReVision Optics Inc Company Overview
    • 5.42.1. ReVision Optics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.43. Royal College of Surgeons in Ireland Company Overview
    • 5.43.1. Royal College of Surgeons in Ireland Pipeline Products & Ongoing Clinical Trials Overview
  • 5.44. Stanford University Company Overview
    • 5.44.1. Stanford University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.45. Studio Oculistico Gualdi Company Overview
    • 5.45.1. Studio Oculistico Gualdi Pipeline Products & Ongoing Clinical Trials Overview
  • 5.46. Tel Aviv University Company Overview
    • 5.46.1. Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.47. The Hong Kong University of Science and Technology Company Overview
    • 5.47.1. The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview
  • 5.48. The University of New South Wales Company Overview
    • 5.48.1. The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview
  • 5.49. UltraVision CLPL Company Overview
    • 5.49.1. UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview
  • 5.50. University of Auckland Company Overview
    • 5.50.1. University of Auckland Pipeline Products & Ongoing Clinical Trials Overview
  • 5.51. University of California San Diego Company Overview
    • 5.51.1. University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
  • 5.52. University of Florida Company Overview
    • 5.52.1. University of Florida Pipeline Products & Ongoing Clinical Trials Overview
  • 5.53. University of Illinois at Chicago Company Overview
    • 5.53.1. University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview
  • 5.54. University of Oxford Company Overview
    • 5.54.1. University of Oxford Pipeline Products & Ongoing Clinical Trials Overview
  • 5.55. University of South Florida Company Overview
    • 5.55.1. University of South Florida Pipeline Products & Ongoing Clinical Trials Overview
  • 5.56. University of Tennessee Company Overview
    • 5.56.1. University of Tennessee Pipeline Products & Ongoing Clinical Trials Overview
  • 5.57. University of Valencia Company Overview
    • 5.57.1. University of Valencia Pipeline Products & Ongoing Clinical Trials Overview
  • 5.58. University of Washington Company Overview
    • 5.58.1. University of Washington Pipeline Products & Ongoing Clinical Trials Overview
  • 5.59. Valeant Pharmaceuticals International Inc Company Overview
    • 5.59.1. Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.60. Va-st Ltd Company Overview
    • 5.60.1. Va-st Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.61. Visioneering Technologies, Inc. Company Overview
    • 5.61.1. Visioneering Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.62. VISTAKON Pharmaceuticals LLC Company Overview
    • 5.62.1. VISTAKON Pharmaceuticals LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.63. Visus Technology, Inc. Company Overview
    • 5.63.1. Visus Technology, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.64. Weill Cornell Medical College Company Overview
    • 5.64.1. Weill Cornell Medical College Pipeline Products & Ongoing Clinical Trials Overview
  • 5.65. Western University Company Overview
    • 5.65.1. Western University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.66. Yolia Health Company Overview
    • 5.66.1. Yolia Health Pipeline Products & Ongoing Clinical Trials Overview
  • 5.67. ZircLight Inc. Company Overview
    • 5.67.1. ZircLight Inc. Pipeline Products & Ongoing Clinical Trials Overview

6. Vision Care- Recent Developments

  • 6.1. Nov 16, 2016: New Head of the ZEISS Semiconductor Manufacturing Technology Business Group
  • 6.2. Nov 10, 2016: Alcon introduces new AIR OPTIX plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
  • 6.3. Nov 10, 2016: ReVision Optics Raises USD32 Million in Venture Financing
  • 6.4. Nov 10, 2016: NovaBay Pharmaceuticals Reports 2016 Third Quarter Financial Results
  • 6.5. Nov 09, 2016: University of Melbourne and National Vision Research Institute of Australia win $1 M grant to develop diamond bionic eye prototype
  • 6.6. Nov 09, 2016: New Study Shows Groundbreaking Contact Lens Therapy Effective in Slowing Myopia Progression in Children by 59% Over Two Years
  • 6.7. Nov 09, 2016: Daniel B. Polley, Ph.D., appointed Director of Lauer Tinnitus Research Center at Mass. Eye and Ear
  • 6.8. Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results
  • 6.9. Nov 07, 2016: Pixium Vision announces the first successful implantation and activation of IRIS II, 150 electrode bionic vision system, in the UK
  • 6.10. Nov 07, 2016: TearLab Reports Third Quarter and September Year-To-Date 2016 Financial Results
  • 6.11. Nov 03, 2016: STAAR Surgical Reports Third Quarter 2016 Results
  • 6.12. Oct 28, 2016: Hoya Reports Second Quarter Results
  • 6.13. Oct 27, 2016: VTI Introduces the NaturalVue Multifocal QuickStart Calculator
  • 6.14. Oct 26, 2016: ZEISS Invests Further 60 Million Euros in the Expansion of the Semiconductor Manufacturing Technology Factory
  • 6.15. Oct 26, 2016: Edmund Optics and Varioptic Announce the Availability of the Variable Focus Arctic Liquid Lens in the EO Catalog
  • 6.16. Oct 25, 2016: Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters
  • 6.17. Oct 21, 2016: Essilor: Nine-Month Consolidated Revenue up 7.8% at Constant Exchange Rates
  • 6.18. Oct 20, 2016: CollPlant Files Registration Statement to Raise up to USD25 Million in IPO
  • 6.19. Oct 18, 2016: LumiThera to Raise USD5 Million in Venture Financing
  • 6.20. Oct 17, 2016: Wearable Artificial Vision Device Shows Promise in Helping People Who Are Legally Blind "Read"
  • 6.21. Oct 13, 2016: Carl Zeiss Meditec appoints Steven C. Schallhorn, MD as Chief Medical Officer
  • 6.22. Oct 12, 2016: Hoya to Acquire Performance Optics for up to USD476 Million
  • 6.23. Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer
  • 6.24. Sep 27, 2016: Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy
  • 6.25. Sep 16, 2016: Johnson & Johnson to Acquire Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion
  • 6.26. Sep 15, 2016: PFO Global Raises USD0.4 Million in Private Placement of Debenture
  • 6.27. Sep 13, 2016: Novartis Raises USD561.78 Million in Public Offering of International Bonds Due 2028
  • 6.28. Sep 13, 2016: Novartis Raises USD1.40 Billion in Public Offering of International Bonds Due 2023
  • 6.29. Sep 12, 2016: Pixium Vision receives clinical trial approval from Spanish Ministry of Health for 150 electrode IRIS II bionic vision system
  • 6.30. Sep 09, 2016: KKR Invests USD66 Million in AcuFocus
  • 6.31. Sep 01, 2016: The Cooper Companies CFO Gregory W. Matz to Retire; Albert G. White Named Successor in Planned Transition
  • 6.32. Sep 01, 2016: The Cooper Companies Announces Third Quarter 2016 Results
  • 6.33. Aug 31, 2016: ReVision Optics Announces First U.S. Commercial Cases of Raindrop Near Vision Inlay
  • 6.34. Aug 30, 2016: FDA-Approved Raindrop Near Vision Inlay Corrects Blurry Reading Vision -- Now Available in Utah for the First Time
  • 6.35. Aug 29, 2016: Drug-dispensing contact lens effectively lowers eye pressure in pre-clinical glaucoma model
  • 6.36. Aug 29, 2016: Drug Dispensing Contact lens Effectively Lowers Eye Pressure in Pre clinical Glaucoma Model
  • 6.37. Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer
  • 6.38. Aug 18, 2016: ReVision Optics Secures USD10 Million from Square 1 Bank
  • 6.39. Aug 18, 2016: Luiz de Freitas Joins VISION EASE as Commercial Director for Mexico
  • 6.40. Aug 15, 2016: CooperVision Unveils Avaira Vitality Sphere and Toric Two-Week Contact Lenses
  • 6.41. Aug 12, 2016: Carl Zeiss Meditec Grows in Ophthalmology and Microsurgery
  • 6.42. Aug 11, 2016: Outcomes of Presbia Microlens Surgeries in Korean Study Demonstrate Excellent Results
  • 6.43. Aug 11, 2016: NovaBay Pharmaceuticals Reports 2016 Second Quarter Financial Results
  • 6.44. Aug 10, 2016: ReVision Optics Names Dr. Nick J. Manesis Vice President of R&D
  • 6.45. Aug 10, 2016: Acufocus Raises USD2 Million in Venture Financing
  • 6.46. Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation
  • 6.47. Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results
  • 6.48. Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team
  • 6.49. Aug 03, 2016: STAAR Surgical Reports Second Quarter 2016 Results
  • 6.50. Aug 03, 2016: TearLab Reports Second Quarter and June Year-To-Date 2016 Financial Results
  • 6.51. Aug 01, 2016: Study Shows Corneal Structural Changes Induced by ReVision Optics' Raindrop Near Vision Inlay Significantly Improve Near and Intermediate Vision in Subjects with Presbyopia
  • 6.52. Aug 01, 2016: NovaBay Pharma Raises USD4 Million in Second and Final Tranche of Private Placement of Units
  • 6.53. Aug 01, 2016: Essilor International: Improving Lives by Improving Sight
  • 6.54. Jul 29, 2016: Essilor - First-Half 2016 Results: Revenue Up 8.1% Excluding the Currency Effect
  • 6.55. Jul 29, 2016: Hoya Reports First Quarter Financial Results
  • 6.56. Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors
  • 6.57. Jul 27, 2016: Carl Zeiss Meditec Recruits James V. Mazzo to Lead Its Newly Consolidated Ophthalmology Organization
  • 6.58. Jul 25, 2016: Pixium Vision Announces CE Mark Approval of IRIS II, Its First Bionic Vision System
  • 6.59. Jul 25, 2016: ReVision Optics Appoints Frank Shields Vice President of Sales Worldwide
  • 6.60. Jul 20, 2016: Pixium Vision First Half 2016 Financial Results and Business Update
  • 6.61. Jul 20, 2016: Carl Zeiss Meditec announces change to Management Board
  • 6.62. Jul 19, 2016: Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects
  • 6.63. Jul 18, 2016: Combined Cataract and Presbia Microlens Surgeries Demonstrate Excellent Results and Patient Satisfaction in Near-Vision Improvement
  • 6.64. Jul 14, 2016: Alcon launches Dailies Total1 Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
  • 6.65. Jul 14, 2016: China Grand Pharma Raises USD22 Million in Private Placement of Shares
  • 6.66. Jul 11, 2016: Presbia to Participate in the 2016 Australasian Society of Cataract and Refractive Surgeons 20th Annual Conference
  • 6.67. Jul 07, 2016: Allergan Demonstrates a Strong Commitment to America's First Responders Donating Over $1 Million Worth of REFRESH Eye Drops
  • 6.68. Jul 06, 2016: U.S. patent trial and appeal board grants ZEISS' petition and institutes IPR against NPE patent holder AMI
  • 6.69. Jul 06, 2016: Rayner Continues Growth in Europe with Direct Presence in Italy

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Vision Care - Pipeline Products by Stage of Development
  • Table 2: Vision Care - Pipeline Products by Segment
  • Table 3: Vision Care - Pipeline Products by Territory
  • Table 4: Vision Care - Pipeline Products by Regulatory Path
  • Table 5: Vision Care - Pipeline Products by Estimated Approval Date
  • Table 6: Vision Care - Ongoing Clinical Trials
  • Table 7: Vision Care Companies - Pipeline Products by Stage of Development
  • Table 8: Vision Care - Pipeline Products by Stage of Development
  • Table 9: Adventus Technology Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 10: Corneal Onlay - Product Status
  • Table 11: Corneal Onlay - Product Description
  • Table 12: Aeon Astron Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 13: Biolens - Product Status
  • Table 14: Biolens - Product Description
  • Table 15: Body Organ Contact Lens - Product Status
  • Table 16: Body Organ Contact Lens - Product Description
  • Table 17: Alcon, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 18: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Status
  • Table 19: AIR OPTIX Plus HydraGlyde Monthly Replacement Clear And Color Lens - Product Description
  • Table 20: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Product Status
  • Table 21: AIR OPTIX Plus HydraGlyde Monthly Replacement Contact Lenses - Product Description
  • Table 22: AIR OPTIX Plus HydraGlyde Monthly Replacement Multifocal Lens - Product Status
  • Table 23: AIR OPTIX Plus HydraGlyde Monthly Replacement Multifocal Lens - Product Description
  • Table 24: AIR OPTIX Plus HydraGlyde Monthly Replacement Toric Lens - Product Status
  • Table 25: AIR OPTIX Plus HydraGlyde Monthly Replacement Toric Lens - Product Description
  • Table 26: Dailies Total 1 Colors SiHy Lens - Product Status
  • Table 27: Dailies Total 1 Colors SiHy Lens - Product Description
  • Table 28: Dailies Total 1 Toric SiHy Lens - Product Status
  • Table 29: Dailies Total 1 Toric SiHy Lens - Product Description
  • Table 30: Smart Lens - Diabetes - Product Status
  • Table 31: Smart Lens - Diabetes - Product Description
  • Table 32: Weekly WG SiHy Lens - Product Status
  • Table 33: Weekly WG SiHy Lens - Product Description
  • Table 34: Apeliotus Ophthalmics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 35: Comfort Lens - Product Status
  • Table 36: Comfort Lens - Product Description
  • Table 37: Contact Lens - Glaucoma - Product Status
  • Table 38: Contact Lens - Glaucoma - Product Description
  • Table 39: Auburn University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 40: Smart Contact Lenses - Product Status
  • Table 41: Smart Contact Lenses - Product Description
  • Table 42: Axcelon Biopolymers Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 43: MC - PHEMA Based Contact Lens - Product Status
  • Table 44: MC - PHEMA Based Contact Lens - Product Description
  • Table 45: Bar-Ilan University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 46: Bionic Contact Lens - Product Status
  • Table 47: Bionic Contact Lens - Product Description
  • Table 48: Bausch & Lomb Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 49: Ultra Plus Powers Lens - Product Status
  • Table 50: Ultra Plus Powers Lens - Product Description
  • Table 51: Ultra Toric Lens - Product Status
  • Table 52: Ultra Toric Lens - Product Description
  • Table 53: Bionic Eye Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 54: Retinal Prosthesis System - Product Status
  • Table 55: Retinal Prosthesis System - Product Description
  • Table 56: Bionic Vision Australia Pipeline Products & Ongoing Clinical Trials Overview
  • Table 57: High-Acuity Device With 1024 Electrodes - Product Status
  • Table 58: High-Acuity Device With 1024 Electrodes - Product Description
  • Table 59: Wide-View Device With 24-channel - Product Status
  • Table 60: Wide-View Device With 24-channel - Product Description
  • Table 61: Wide-View Device With 44-channel - Product Status
  • Table 62: Wide-View Device With 44-channel - Product Description
  • Table 63: Wide-View Device With 98 Electrodes - Product Status
  • Table 64: Wide-View Device With 98 Electrodes - Product Description
  • Table 65: Children's Hospital Boston Pipeline Products & Ongoing Clinical Trials Overview
  • Table 66: Contact Lens Drug Delivery Device - Product Status
  • Table 67: Contact Lens Drug Delivery Device - Product Description
  • Table 68: Consejo Superior de Investigaciones Cientificas Pipeline Products & Ongoing Clinical Trials Overview
  • Table 69: Reduced Optical Instrument - Product Status
  • Table 70: Reduced Optical Instrument - Product Description
  • Table 71: CooperVision Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 72: Biofinity Energys - Product Status
  • Table 73: Biofinity Energys - Product Description
  • Table 74: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Status
  • Table 75: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Product Description
  • Table 76: SiH Multifocal - Product Status
  • Table 77: SiH Multifocal - Product Description
  • Table 78: CooperVision Inc - Ongoing Clinical Trials Overview
  • Table 79: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - A Multi-center Dispensing Clinical Evaluation of MiSight Lenses
  • Table 80: MiSight Dual-Focus Myopia Control 1-Day Soft Contact Lens - Efficacy and Safety of MiSight Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial
  • Table 81: Cornea Biosciences Pipeline Products & Ongoing Clinical Trials Overview
  • Table 82: Bioengineered Cornea - Product Status
  • Table 83: Bioengineered Cornea - Product Description
  • Table 84: Cornell University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 85: Prosthetic Retinal Device - Product Status
  • Table 86: Prosthetic Retinal Device - Product Description
  • Table 87: EP Global Communications, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 88: EP Global Contact Lens - Product Status
  • Table 89: EP Global Contact Lens - Product Description
  • Table 90: eSight Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 91: evSpex - Product Status
  • Table 92: evSpex - Product Description
  • Table 93: Euclid Systems Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 94: Drug-Eluting Contact Lenses - Product Status
  • Table 95: Drug-Eluting Contact Lenses - Product Description
  • Table 96: Eyenovations Pipeline Products & Ongoing Clinical Trials Overview
  • Table 97: Drug Dispensing Contact Lens - Product Status
  • Table 98: Drug Dispensing Contact Lens - Product Description
  • Table 99: EyeYon Medical Pipeline Products & Ongoing Clinical Trials Overview
  • Table 100: DSPEK - Product Status
  • Table 101: DSPEK - Product Description
  • Table 102: iBionics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 103: iBIONICS Diamond Eye - Product Status
  • Table 104: iBIONICS Diamond Eye - Product Description
  • Table 105: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview
  • Table 106: Contact Lens - Product Status
  • Table 107: Contact Lens - Product Description
  • Table 108: iSTAR Medical SA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 109: STARvue - Product Status
  • Table 110: STARvue - Product Description
  • Table 111: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 112: Intra-corneal Implant - Product Status
  • Table 113: Intra-corneal Implant - Product Description
  • Table 114: Johnson & Johnson Vision Care Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 115: 1-DAY ACUVUE Multifocal Contact Lens - Product Status
  • Table 116: 1-DAY ACUVUE Multifocal Contact Lens - Product Description
  • Table 117: Anti-allergic Contact Lens - Product Status
  • Table 118: Anti-allergic Contact Lens - Product Description
  • Table 119: Massachusetts Eye and Ear Infirmary Pipeline Products & Ongoing Clinical Trials Overview
  • Table 120: Therapeutic Contact Lens - Product Status
  • Table 121: Therapeutic Contact Lens - Product Description
  • Table 122: McGill University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 123: Portable System - Amblyopia - Product Status
  • Table 124: Portable System - Amblyopia - Product Description
  • Table 125: Mercy Research and Development Pipeline Products & Ongoing Clinical Trials Overview
  • Table 126: First Aid Lens - Product Status
  • Table 127: First Aid Lens - Product Description
  • Table 128: Healing Lens - Product Status
  • Table 129: Healing Lens - Product Description
  • Table 130: Meta Biomed Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 131: Artificial Cornea - Product Status
  • Table 132: Artificial Cornea - Product Description
  • Table 133: Microbiosensor Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 134: MicroBioSensor-Contact Lens - Product Status
  • Table 135: MicroBioSensor-Contact Lens - Product Description
  • Table 136: Monash University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 137: Monash Vision - Product Status
  • Table 138: Monash Vision - Product Description
  • Table 139: Nano Retina, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 140: NR600 Implant - Product Status
  • Table 141: NR600 Implant - Product Description
  • Table 142: Novartis AG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 143: CLM041 - Product Status
  • Table 144: CLM041 - Product Description
  • Table 145: Ocular Dynamics, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 146: Contact Lens - Dry Eye Disease - Product Status
  • Table 147: Contact Lens - Dry Eye Disease - Product Description
  • Table 148: Ocutec Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 149: Third PEG Hydrogel Contact Lens - Product Status
  • Table 150: Third PEG Hydrogel Contact Lens - Product Description
  • Table 151: PixelOptics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 152: Behold - Product Status
  • Table 153: Behold - Product Description
  • Table 154: Pixium Vision Pipeline Products & Ongoing Clinical Trials Overview
  • Table 155: IRIS II Bionic Vision System - Product Status
  • Table 156: IRIS II Bionic Vision System - Product Description
  • Table 157: PRIMA - Product Status
  • Table 158: PRIMA - Product Description
  • Table 159: Presbia Plc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 160: Presbia Flexivue Microlens - Product Status
  • Table 161: Presbia Flexivue Microlens - Product Description
  • Table 162: Presbia Plc - Ongoing Clinical Trials Overview
  • Table 163: Presbia Flexivue Microlens - A Phase II trial of Presbia Flexivue Microlens for The Treatment of Presbyopia
  • Table 164: Presbia Flexivue Microlens - Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens for the Improvement of Near Vision in Emmetropic Presbyopes
  • Table 165: Queensland University of Technology Pipeline Products & Ongoing Clinical Trials Overview
  • Table 166: Ophthalmic Lenses - Product Status
  • Table 167: Ophthalmic Lenses - Product Description
  • Table 168: Refocus Group Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 169: VisAbility Implant System - Product Status
  • Table 170: VisAbility Implant System - Product Description
  • Table 171: Refocus Group Inc - Ongoing Clinical Trials Overview
  • Table 172: VisAbility Implant System - A Prospective, Multicenter Clinical Trial of the VisAbility Implant System for Improvement of Near Visual Acuity in Presbyopic Patients
  • Table 173: RetMap Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 174: CLEAr Lens - Product Status
  • Table 175: CLEAr Lens - Product Description
  • Table 176: ReVision Optics Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 177: Raindrop Near Vision Inlay - Product Status
  • Table 178: Raindrop Near Vision Inlay - Product Description
  • Table 179: ReVision Optics Inc - Ongoing Clinical Trials Overview
  • Table 180: Raindrop Near Vision Inlay - A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the ReVision Optics, Inc., Raindrop Near Vision Inlay for the Improvement of Near and Intermediate Vision in Pseudophakic Subjects
  • Table 181: Royal College of Surgeons in Ireland Pipeline Products & Ongoing Clinical Trials Overview
  • Table 182: OcularColl - Product Status
  • Table 183: OcularColl - Product Description
  • Table 184: Stanford University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 185: Biological Neural Network Based Retinal Prosthesis - Product Status
  • Table 186: Biological Neural Network Based Retinal Prosthesis - Product Description
  • Table 187: Polymer Network Hydrogel Contact Lens - Product Status
  • Table 188: Polymer Network Hydrogel Contact Lens - Product Description
  • Table 189: Studio Oculistico Gualdi Pipeline Products & Ongoing Clinical Trials Overview
  • Table 190: PEARL Inlay - Product Status
  • Table 191: PEARL Inlay - Product Description
  • Table 192: Tel Aviv University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 193: Bionic Eye - Product Status
  • Table 194: Bionic Eye - Product Description
  • Table 195: The Hong Kong University of Science and Technology Pipeline Products & Ongoing Clinical Trials Overview
  • Table 196: Resonance Circuit Sensor Contact Lens - Product Status
  • Table 197: Resonance Circuit Sensor Contact Lens - Product Description
  • Table 198: The University of New South Wales Pipeline Products & Ongoing Clinical Trials Overview
  • Table 199: Stem Cell Contact Lens - Product Status
  • Table 200: Stem Cell Contact Lens - Product Description
  • Table 201: UltraVision CLPL Pipeline Products & Ongoing Clinical Trials Overview
  • Table 202: Contact Lenses - Product Status
  • Table 203: Contact Lenses - Product Description
  • Table 204: University of Auckland Pipeline Products & Ongoing Clinical Trials Overview
  • Table 205: Vision Screening System - Product Status
  • Table 206: Vision Screening System - Product Description
  • Table 207: University of California San Diego Pipeline Products & Ongoing Clinical Trials Overview
  • Table 208: Aerated Contact Lens - Product Status
  • Table 209: Aerated Contact Lens - Product Description
  • Table 210: Telescopic Contact Lens - Product Status
  • Table 211: Telescopic Contact Lens - Product Description
  • Table 212: University of Florida Pipeline Products & Ongoing Clinical Trials Overview
  • Table 213: Vitamin E - Packed Lenses - Product Status
  • Table 214: Vitamin E - Packed Lenses - Product Description
  • Table 215: University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview
  • Table 216: Keratoprosthesis - Product Status
  • Table 217: Keratoprosthesis - Product Description
  • Table 218: Transcorneal Telescope - Product Status
  • Table 219: Transcorneal Telescope - Product Description
  • Table 220: University of Oxford Pipeline Products & Ongoing Clinical Trials Overview
  • Table 221: Bionic Glass - Product Status
  • Table 222: Bionic Glass - Product Description
  • Table 223: University of South Florida Pipeline Products & Ongoing Clinical Trials Overview
  • Table 224: Corneal Replacement Prosthesis - Product Status
  • Table 225: Corneal Replacement Prosthesis - Product Description
  • Table 226: University of Tennessee Pipeline Products & Ongoing Clinical Trials Overview
  • Table 227: Dynamic Ocular Evaluation System - Product Status
  • Table 228: Dynamic Ocular Evaluation System - Product Description
  • Table 229: University of Valencia Pipeline Products & Ongoing Clinical Trials Overview
  • Table 230: Multifocal Contact Lens - Myopia - Product Status
  • Table 231: Multifocal Contact Lens - Myopia - Product Description
  • Table 232: Multifocal Contact Lens - Presbyopia - Product Status
  • Table 233: Multifocal Contact Lens - Presbyopia - Product Description
  • Table 234: University of Washington Pipeline Products & Ongoing Clinical Trials Overview
  • Table 235: Bionic Contact Lens - Product Status
  • Table 236: Bionic Contact Lens - Product Description
  • Table 237: Solar Powered Augmented Lenses - Product Status
  • Table 238: Solar Powered Augmented Lenses - Product Description
  • Table 239: Valeant Pharmaceuticals International Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 240: BLC - 001: SVS - Product Status
  • Table 241: BLC - 001: SVS - Product Description
  • Table 242: BLC - 002: SVS - Product Status
  • Table 243: BLC - 002: SVS - Product Description
  • Table 244: BLC - 003: SVS/MF/fA - Product Status
  • Table 245: BLC - 003: SVS/MF/fA - Product Description
  • Table 246: BLC - 004: Toric - Product Status
  • Table 247: BLC - 004: Toric - Product Description

List of Figures

  • Figure 1: Vision Care - Pipeline Products by Stage of Development
  • Figure 2: Vision Care - Pipeline Products by Segment
  • Figure 3: Vision Care - Pipeline Products by Territory
  • Figure 4: Vision Care - Pipeline Products by Regulatory Path
  • Figure 5: Vision Care - Pipeline Products by Estimated Approval Date
  • Figure 6: Vision Care - Ongoing Clinical Trials
Back to Top